Commentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection

Metabolism. 2020 Aug:109:154272. doi: 10.1016/j.metabol.2020.154272. Epub 2020 May 27.

Authors

Irene Caruso¹, Angelo Cignarelli¹, Annalisa Natalicchio¹, Sebastio Perrini¹, Luigi Laviola¹, Francesco Giorgino²

Affiliations

¹ Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
² Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy. Electronic address: francesco.giorgino@uniba.it.

PMID: 32470349
DOI: 10.1016/j.metabol.2020.154272

No abstract available

Keywords: Cardiovascular disease; GLP-1 receptor agonist; HbA1c; Outcome trial; Stroke.

Publication types

Review

MeSH terms

Aged
Blood Glucose / physiology*
Cardiovascular Diseases / etiology
Cardiovascular Diseases / prevention & control*
Clinical Trials as Topic
Female
Glucagon-Like Peptide-1 Receptor / agonists*
Glycated Hemoglobin / drug effects
Homeostasis
Humans
Male
Protective Agents / pharmacology*

Substances

Blood Glucose
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin A
Protective Agents
hemoglobin A1c protein, human